Severity of Gastrointestinal Side Effects of Metformin Tablet Compared to Metformin Capsule in Type 2 Diabetes Mellitus Patients
Open Access
- 1 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 6 (2) , 73-76
Abstract
Objective: This study was designed to compare the severity of gastrointestinal (GI) side effects in Type 2 diabetes mellitus (DM) patients receiving tablet or capsule forms of metformin. Methods: In this prospective interventional study, patients were evaluated from June to November 2016 at DM clinics affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. Adult patients with Type 2 DM who were eligible for inclusion criteria switched from metformin tablet to metformin capsule. Hemoglobin A1c (HbA1c), GI side effects, and patient satisfaction based on visual analog scale (VAS) were assessed during a 6-week follow-up of receiving metformin capsule. Findings: One hundred and three patients were evaluated, and 75 patients participated in this study. At the baseline, 40 patients (53.3%) had GI side effects due to metformin tablet which was reduced to 16 patients (21.3%) after switching to metformin capsule (P = 0.001). There was also an improvement in HbA1c (from 7 to 6.8,P < 0.0001). The results of patients’ satisfaction based on VAS and numeric rating scale indicated that in 59 patients (78.67%), GI side effects were reduced after switching to metformin capsule (mean score: 7.2 with the range of 6–9) while 16 patients stated no treatment preference. Conclusion: Switching to metformin capsule may result in less GI side effects, with no further side effect complications.Keywords
This publication has 16 references indexed in Scilit:
- Understanding and overcoming metformin gastrointestinal intoleranceDiabetes, Obesity and Metabolism, 2016
- Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.2016
- Metformin and the gastrointestinal tractDiabetologia, 2016
- Therapeutic Use of Metformin in Prediabetes and Diabetes PreventionDrugs, 2015
- Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose LevelsJournal of Diabetes Science and Technology, 2015
- Application of QbD Principles for the Evaluation of Empty Hard Capsules as an Input Parameter in Formulation Development and ManufacturingAAPS PharmSciTech, 2014
- Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in AsiaJournal of Diabetes, 2012
- Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short‐Form McGill Pain Questionnaire (SF‐MPQ), Chronic Pain Grade Scale (CPGS), Short Form‐36 Bodily Pain Scale (SF‐36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)Arthritis Care & Research, 2011
- Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes MellitusPostgraduate Medicine, 2011
- A European Evidence-Based Guideline for the Prevention of Type 2 DiabetesHormone and Metabolic Research, 2010